Multidirectional in silico and in vitro Research for the Pharmaceutical Potential of Fibigia Clypeata (L.) Medik: Phytochemical, Antimicrobial, and Antimyeloma Properties

Basit Öğe Kaydı
dc.contributor.authorUnver, Tuba
dc.contributor.authorUzuner, Ugur
dc.contributor.authorAkcora-Yildiz, Dilara
dc.contributor.authorGurhan, Ismet
dc.contributor.authorArkan, Caglar
dc.contributor.authorOzdemir, Zeynep
dc.date.accessioned2026-04-04T13:37:37Z
dc.date.available2026-04-04T13:37:37Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractFibigia clypeata (L.) Medik, a member of the Brassicaceae, has been the subject of limited research on its pharmaceutical and medicinal properties. This study aims to evaluate the phytochemical, antimicrobial, and antimyeloma properties of F. clypeata extracts and detail these results in silico analyses. The minimum inhibitory concentration (MIC) of F. clypeata extracts was determined using dilution methods, and antimyeloma activity was determined using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) assay. The findings were evaluated by in silico analyses and correlated with the results of liquid chromatography-high-resolution mass spectrometry. The inhibitory effect of the water extract (MIC is 15 mg mL-1 against bacterial strains; MICs are between 7.5 and 3.75 mg mL-1 against Candida strains) was determined to be more potent than methanol extract (MIC is 60 mg mL-1 against bacterial strains; MICs are between 30 mg/mL and 7.50 mg mL-1 against Candida strains). Molecular docking findings revealed that cyanidin 3-rutinoside chloride showed the highest binding affinity to Staphylococcus aureus MurB, Candida parapsilosis, and Candida albicans dihydrofolate reductases and the antitumor target human epidermal growth factor receptor protein. Based on MTT results, F. clypeata extracts significantly decreased cell viability dose-dependently in three human MM and noncancerous MCF10A cell lines. F. clypeata harbor valuable antimicrobial and moderately anticancerogenic compounds.
dc.description.sponsorshipScientific and Technological Research Council of Turkiye (TUBITAK)
dc.description.sponsorshipWe would like to thank Assoc. Prof. Selcen Celik Uzuner for sharing MCF10A cell lines with us without hesitation. We thank Prof. Dr. Turan Arabac & imath; for the help in identifying the plant and the Malatya-Puturge natives for supporting us with their efforts in collecting the plant. We also thank the Scientific and Technological Research Council of Turkiye (TUBITAK) for providing open access funding.
dc.identifier.doi10.1002/open.202500036
dc.identifier.issn2191-1363
dc.identifier.issue12
dc.identifier.orcid0000-0003-2586-4385
dc.identifier.orcid0000-0003-4559-2305
dc.identifier.orcid0000-0002-5308-3730
dc.identifier.orcid0000-0002-8655-2716
dc.identifier.orcid0000-0001-7017-2447
dc.identifier.pmid40904263
dc.identifier.scopus2-s2.0-105014887375
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://doi.org/10.1002/open.202500036
dc.identifier.urihttps://hdl.handle.net/11616/109946
dc.identifier.volume14
dc.identifier.wosWOS:001562946300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofChemistryopen
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectantimicrobial activity
dc.subjectantimyeloma activity
dc.subjectFibigia clypeata
dc.subjectmolecular docking
dc.subjectnatural pharmaceuticals
dc.titleMultidirectional in silico and in vitro Research for the Pharmaceutical Potential of Fibigia Clypeata (L.) Medik: Phytochemical, Antimicrobial, and Antimyeloma Properties
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu